Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice

Journal of Bone and Mineral Research

Volumn 25, Issue 7, 2010, Pages 1668-1679

  Kikuiri, Takashi ^a   Kim, Insoo ^a   Yamaza, Takyoshi ^a   Akiyama, Kentaro ^a   Zhang, Qunzhou ^a   Li, Yunsheng ^b   Chen, Chider ^a   Chen, WanJun ^c   Wang, Songlin ^b   Le, Anh D ^a   Shi, Songtao ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Bisphosphonate; Interleukin 17; Mesenchymal stem cell; Osteonecrosis; Th17; Treg

Indexed keywords

DEXAMETHASONE; ZOLEDRONIC ACID;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; JAW OSTEONECROSIS; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; TH17 CELL;

ANIMALS; CYTOKINES; DEXAMETHASONE; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; FEMALE; IMIDAZOLES; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; JAW DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; MICE, INBRED C57BL; MICE, NUDE; OSTEONECROSIS; T-LYMPHOCYTES, REGULATORY;

EID: 77954721363     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.37     Document Type: Article

References (44)

1. Lipton A. New therapeutic agents for the treatment of bone diseases. Expert Opin Biol Ther. 2006;5:817-832.
2. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.
3. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
4. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.
5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
6. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-377.
7. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86:1013-1021.
8. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122:S33-S45.
9. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol 2009;45:301-308.
10. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008;83:1032-1045.
11. Cetiner S, Sucak GT, Kahraman SA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 2009;27:435-443.
12. Wimalawansa SJ. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 2008;7:491-512.
13. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661. (Pubitemid 34815869)
14. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
15. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 2009;60:18.1-18.12.
16. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003;327:469. (Pubitemid 37056193)
17. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
18. Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA 2006;295:2833-2836.
19. Wilkinson GS, Kuo Y-F, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A Population-Based Analysis. J Natl Cancer Inst 2007;99:1016-1024.
20. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761. (Pubitemid 46780635)
21. Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 2008;3:e2615.
22. Sun L, Akiyama K, Zhang H, et al. Mesenchymal Stem Cell Transplantation Reverses Multi-Organ Dysfunction in Systemic Lupus Erythematosus Mice and Humans. Stem Cells 2009;27:1421-1432.
23. Yamaza T, Miura Y, Akiyama K, et al. Mesenchymal stem cell-mediated ectopic hematopoiesis alleviates aging-related phenotype in immunocompromised mice. Blood 2009;113:2595-2604.
24. Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491.
25. Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008;371:1553-1554. (Pubitemid 351626827)
26. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506. (Pubitemid 350159613)
27. Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory and antiangiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008;26:1047-1055.
28. Iyer SS, Rojas M. Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Exp Opin Biol Ther 2008; 8:569-581. (Pubitemid 351685023)
29. Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 2006;91:1165-1171. (Pubitemid 44408425)
30. Fiore F, Castella B, Nuschak B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007;110:921-927.
31. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007;67:11438-11446. (Pubitemid 350248572)
32. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009;45:164-172.
33. Tang QZ, Bluestone JA. The Foxp 3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008;9:239-944.
34. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-787.
35. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008;28:660-670.
36. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005;7:29-37. (Pubitemid 40214525)
37. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
38. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006;441:235-238.
39. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-333.
40. Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from persons with chronic periodontitis. J Clin Periodontol 2005;2:383-389. (Pubitemid 40569601)
41. Takahashi K, Azuma T, Motohira H, Kinane DF, Kitetsu S. The potential role of interleukin-17 in the immunopathology of periodontal disease. J Clin Periodontol 2005;32:369-374. (Pubitemid 40569599)
42. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004;75:37-43. (Pubitemid 38312768)
43. Hansen T, Kundel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160.
44. Hansen T, Kundel M, James Kirkpatrick C, Weber A. Actinomycosis in infected osteoradionecrosis: underestimated? Hum Pathol 2006;37:61-67.